Sagimet Biosciences (SGMT) said Tuesday the US Food and Drug Administration's Division of Dermatology and Dentistry has cleared its investigational new drug application for TVB-3567.
The company said the clearance allows it to enter clinical development for the treatment of acne, with a first-in-human phase 1 trial planned in 2025.
TVB-3567 is its second fatty acid synthase inhibitor, it said.
Price: 3.37, Change: -0.17, Percent Change: -4.80
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。